SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT

The objective of the SCALE IBT trial (NCT02963935) was to compare the weight loss of liraglutide 3.0 mg, a medication approved by the Food and Drug Administration for chronic weight management, to placebo, both in combination with 56 weeks of intensive behavior therapy (IBT) (i.e. reduced calorie in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Endocr Soc
Main Authors: Shaw Tronieri, Jena, Wadden, Thomas, Sugimoto, Daniel, Lund, Michael, Auerbach, Pernille, Endahl, Lars, Rubino, Domenica
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2019
Assuntos:
Adipose Tissue, Appetite, and Obesity
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552310/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-097
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados